| Autor: |
Schmidt, H., Ehninger, G., Dopfer, R., Blaurock, M., Naumann, R., Einsele, H., Haen, M., Schüch, K., Jaschonek, K., Niethammer, D., Waller, H. |
| Zdroj: |
Blut: Zeitschrift für die Gesamte Blutforschung; 1988, Vol. 57 Issue 3, p139-142, 4p |
| Abstrakt: |
Between 1982 and 1986 51 patients were treated with ciclosporin a (CSA) to prevent graft versus host disease (GvHD) after bone marrow transplantation (BMT). Major side effects of the drug were tremor, hypertension, hepatotoxicity and nephrotoxicity. Acute GvHD 0° to II° occurred in 80% of our patients, and GvHD III° and IV° in 20% despite the use of CSA. Two to four days before the onset of GvHD, CSA serum levels were significantly lower on the average in patients who developed GvHD III° and IV° compared to the others. Our data indicate that plasma CSA concentrations higher than 250 ng/ml should be achieved to reduce the severity of GvHD after BMT. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
